Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials

被引：0

作者：

Treat, J.

Scagliotti, G.

Peng, G.

Monberg, M. J.

Obasaju, C. K.

机构：

[1] Eli Lilly & Co, Indianapolis, IN 46285 USA

[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Turin, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.e18004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e18004

引用

页数：1

共 50 条

[41] Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
Gervais, Radj
Robinet, Gilles
Clement-Duchene, Christelle
Denis, Fabrice
El Kouri, Claude
Martin, Philippe
Chouaki, Nadia
Bourayou, Nawel
Morere, Jean-Francois
LUNG CANCER, 2013, 80 (02) : 185 - 190
[42] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
Orlandi-Jorquera, L
Orlandi, F
Galaz, P
Gamargo, C
Salman, P
Yanez, M
ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
[43] Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer a multicenter, randomized, phase II trial
Scagliotti, GV
Kortsik, C
Dark, GG
Price, A
Manegold, C
Rosell, R
O'Brien, M
Peterson, PM
Castellano, D
Selvaggi, G
Novello, S
Blatter, J
Kayitalire, L
Crino, L
Paz-Ares, L
CLINICAL CANCER RESEARCH, 2005, 11 (02) : 690 - 696
[44] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
Benekli, Mustafa
Gunaydin, Yusuf
Inanc, Mevlude
Ozkan, Metin
Demirci, Ayse
Demirci, Umut
Suner, Ali
Karaca, Halit
Tonyali, Onder
Berk, Veli
Buyukberber, Suleyman
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
[45] A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC)
Belani, Chandra Prakash
Yamamoto, Nobuyuki
Bondarenko, Igor
Orlov, Sergey V.
Tang, Jie
Niethammer, Andreas G.
Ingrosso, Antonella
Kim, Sinil
Scagliotti, Giorgio
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[46] A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)
Letsa, I.
Mikropoulos, C.
Burcombe, R.
Visioli, A.
Sevitt, T.
Cominos, M.
Beesley, S.
LUNG CANCER, 2011, 71 : S7 - S7
[47] Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer
Pereira, A. A. R.
Lessa, R. C.
Souza, C. E. P.
Pinto, F. A. I.
Gagliato, D. M.
Santos, E. S.
Fanelli, M. F.
Rinck, J. A.
Dettino, A. A.
Nicolau, U. R.
Chinen, L. T. D.
de Lima, V. C. C.
Pereira, J. R.
Cruz, M. R. D. S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[48] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
Shiraishi, Yoshimasa
Hirai, Humihiko
Yamaguchi, Masafumi
Morodomi, Yosuke
Toyozawa, Ryo
Inamasu, Eiko
Kojo, Miyako
Toyokawa, Gouji
Takenaka, Tomoyoshi
Seto, Takashi
Takenoyama, Mitsuhiro
Ichinose, Yukito
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
[49] AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).
Besse, Benjamin
Felip, Enriqueta
Clifford, Corinne
Louie-Gao, Melinda
Green, Jennifer
Turner, Christopher D.
Popat, Sanjay
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
Murakami, Shuji
Saito, Haruhiro
Karino, Fumi
Kondo, Tetsuro
Oshita, Fumihiro
Yamada, Kouzo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →